Europe Fibrotic Diseases Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2031

Fibrotic Diseases Treatment Market Analysis

The European treatment market for fibrotic diseases is expected to grow significantly in the coming years. Factors such as the increasing prevalence of fibrotic diseases, rising awareness about treatment options, and advancements in medical technology are driving this growth. The region's well-established healthcare infrastructure and favorable regulatory environment also contribute to market expansion. In addition, the growing elderly population in Europe, who are more prone to fibrotic diseases, is expected to fuel market growth. The increasing adoption of novel therapies and biologics for fibrotic diseases is another key trend in the region.  

Fibrotic Diseases Treatment Market Size

Europe fibrotic diseases treatment market size was valued at USD 6.18 billion in 2023 and is projected to reach USD 11.80 billion by 2031, with a CAGR of 8.42% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation       

Fibrotic Diseases Treatment Market Definition

Fibrotic diseases treatment refers to the medical interventions and therapies aimed at managing and treating conditions characterized by the development of excessive fibrous connective tissue, or fibrosis, in organs and tissues. Fibrosis is a common feature of many chronic diseases and can lead to organ dysfunction and failure. Treatment strategies for fibrotic diseases typically focus on reducing inflammation, slowing down or halting the progression of fibrosis, and managing symptoms to improve quality of life.                             

Fibrotic Diseases Treatment Market Dynamics

Drivers

• Increasing Prevalence of Fibrotic Diseases     

The prevalence of fibrotic diseases, such as idiopathic pulmonary fibrosis (IPF) and liver fibrosis, is on the rise, primarily due to factors such as aging populations and the increasing incidence of lifestyle-related diseases. As people live longer, the likelihood of developing fibrotic diseases increases, driving the demand for effective treatments and boosting market growth. Additionally, lifestyle factors such as smoking, obesity, and poor diet contribute to the development of fibrotic diseases, further increasing the prevalence and driving market growth.       

• Advancements in Treatment Technologies       

Technological advancements in the field of fibrotic diseases treatment have revolutionized the way these conditions are managed. Novel therapies and biologics offer more targeted and effective treatments, improving patient outcomes and quality of life. These advancements have led to a shift towards personalized medicine, where treatments are tailored to individual patients based on their specific needs and genetic makeup. This has significantly improved the efficacy of treatments and is a major driver for market growth.            

• Rising Awareness and Diagnosis Rates      

Increasing awareness about fibrotic diseases among both healthcare professionals and the general public has led to improved diagnosis rates and early detection. This has enabled patients to receive timely treatment, leading to better outcomes and driving market growth. Improved diagnostic capabilities, such as advanced imaging techniques and biomarker tests, have also contributed to the early detection of fibrotic diseases. As awareness continues to grow and diagnostic methods improve, more patients are expected to seek treatment, further driving market growth.

Opportunities

• Growing Healthcare Expenditure   

Countries with aging populations are witnessing a rise in healthcare spending, particularly on advanced treatments for chronic conditions such as fibrotic diseases. This increase in expenditure is driven by the need to provide high-quality care to an aging population, as well as advancements in medical technology that offer more effective treatment options. As healthcare expenditure continues to grow, it is expected to drive market growth for fibrotic disease treatments, providing companies with opportunities to expand their market presence.

• Supportive Government Initiatives    

Governments across Europe are implementing policies to enhance healthcare delivery systems and ensure that patients have access to high-quality care. These initiatives include investments in healthcare infrastructure, increased funding for research and development, and efforts to reduce barriers to accessing healthcare services. As a result, the market for fibrotic disease treatments is expected to benefit from these supportive government initiatives, providing companies with opportunities to expand their market reach and develop new treatment options.

Restraints/Challenges

• Side Effects of Treatment             

Many existing treatments for fibrotic diseases, such as steroids and immunosuppressants, can cause adverse effects such as weight gain, mood changes, and increased susceptibility to infections. These side effects can lead to patient discomfort and non-compliance with treatment regimens, ultimately affecting the market for fibrotic disease treatments. The potential side effects of current treatments for fibrotic diseases can be a significant limitation to their use and can impact market growth.     

• High Treatment Costs 

The cost of medications, medical procedures, and hospitalization for fibrotic diseases can be substantial, placing a financial burden on patients and healthcare systems. This high cost can limit access to treatment for many patients, particularly those in developing countries or without adequate insurance coverage. The high cost of treatment for fibrotic diseases is a major restraint for market growth, particularly in countries with limited healthcare budgets.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Fibrotic Diseases Treatment Market Scope

The fibrotic diseases treatment market is categorized into four notable segments based on treatment, application, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Medication
• Organ Transplantation
• Oxygen Therapy
• Others

Application

• Idiopathic pulmonary fibrosis
• Hepatic cirrhosis
• Renal fibrosis
• Cutaneous fibrosis
• Others

End User

• Government organization
• Hospitals
• Academic and research institutes
• Others

Distribution Channel

• Hospital pharmacy
• Retail pharmacy
• Others

Europe Fibrotic Diseases Treatment Market Regional Analysis

The market is analyzed and market size insights and trends are provided by country, treatment, application, end user, and distribution channel as referenced above.

The countries covered in the market are Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, and rest of Europe.

Germany is expected to dominate and show significant growth in the market due to advancements in technology within developing regions. The country's strong position is bolstered by its robust healthcare infrastructure and a focus on innovation, particularly in fibrotic diseases. Germany's proactive approach to research and development, coupled with a favorable regulatory environment, positions it as a key player in advancing treatment options for fibrotic diseases across Europe.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Fibrotic Diseases Treatment Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Some of the major players operating in the market are:

• Boehringer Ingelheim International GmbH (Germany)
• AbbVie Inc. (U.S.)
• Redx Pharma Plc (U.K.)
• Bristol-Myers Squibb Company (U.S.)
• Gilead Sciences, Inc. (U.S.)
• KITHER BIOTECH S.R.L. (Italy)
• Verona Pharma plc (U.K.)
• Intercept Pharmaceuticals, Inc. (U.S.)
• Pharmaxis Ltd. (Australia)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sandoz International GmbH (Austria)

Latest Developments in Fibrotic Diseases Treatment Market

• In May 2023, Boehringer Ingelheim announced the initiation of clinical development for its first-in-class IL-11 inhibitor antibody, BI 765423. The Phase 1 study (NCT05658107) aims to assess the safety, tolerability, and pharmacokinetics of the drug in healthy volunteers. Pre-clinical studies have shown that this anti-IL-11 medication has the potential to inhibit and even reverse fibrosis in various fibrotic diseases
• In May 2023, Cumberland Pharmaceuticals Inc. disclosed that the FDA had approved an Investigational New Drug Application (IND) for Phase II research involving patients with Idiopathic Pulmonary Fibrosis (IPF), which is the most prevalent form of progressive fibrosing interstitial lung disease

SKU-69893